Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

32.69 -0.16 (-0.49%)
Official Closing Price Updated: 7:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
These three healthcare stocks to sell are waving red flags at investors who should pay attention or suffer the consequences. 
Via InvestorPlace
Most Active Equity Options For Midday - Friday, Sep. 22
Here are the most active equity options for midday. 
Via Talk Markets
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
The companies tested a key combination in patients with previously untreated bladder cancer. 
Via Investor's Business Daily
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing... 
Via Benzinga
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Many stocks have nosebleed valuations. But not these. 
Via The Motley Fool
2 Dividend Growth Stocks to Buy Right Now
A wise man once said, be greedy when others are fearful. 
Via The Motley Fool
Why NYSE:PFE is a Top Pick for Dividend Investors.
Is PFIZER INC ( NYSE:PFE ) a Good Fit for Dividend Investing? 
Via Chartmill
Check Out What Whales Are Doing With PFE
Via Benzinga
Updated Covid Vaccine US Rollout Hit by Insurance Coverage Delays - What It Means?
As the U.S. 
Via Benzinga
Exposures COVID-19
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
There are always many biotech stocks to avoid and these firms are among the clearest choices currently to steer clear of. 
Via InvestorPlace
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
All three companies should benefit from increased COVID-19 booster sales. 
Via The Motley Fool
Exposures COVID-19
Beware! 3 Nasdaq Stocks Waving Massive Red Flags Right Now.
A range of worries are pulling these Nasdaq stocks to sell lower and clouding the outlook for their share prices. 
Via InvestorPlace
3 Stocks to Avoid Like the Plague Right Now: MRNA, GPS, PTON
The good economic times of the past few years appear to be ending. As such, it's time to exit these three stocks to avoid. 
Via InvestorPlace
Pfizer Stock: Bear vs. Bull
The pharma giant's future financial performance is a matter of debate. 
Via The Motley Fool
Looking At Pfizer's Recent Unusual Options Activity
Via Benzinga
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Bloomberg 
Via Benzinga
First Human Clinical Trials Of A Potentially “Game-Changing Broad Spectrum Antiviral” Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses
--News Direct-- 
Via News Direct
Exposures COVID-19
European Commission Approves GSK/Pfizer-Backed HIV Infection Prevention Drug
The European Commission has approved ViiV Healthcare's Apretude (cabotegravir long-acting (LA) injectable and tablets)  
Via Benzinga
Cramer Says 'I Can't Tell You To Sell It Here,' As Massive Pharma Stock Falls 34% YTD
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Paycom Software, Inc. (NYSE: PAYC) is "one of those fintech companies. 
Via Benzinga
The Top 7 Underrated Dividend Stocks Yielding 3% or More
Investors seeking dependable income and upside should buy these dividend stocks yielding 3% or more, the sooner the better 
Via InvestorPlace
2 Stocks That Sank Hard on Monday
Investors were generally in wait-and-see mode, but not with certain individual stocks. 
Via The Motley Fool
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to... 
Via Benzinga
First Human Clinical Trials Of A Potentially "Game-Changing Broad Spectrum Antiviral" Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses
As COVID cases begin to rise again, heralding the beginning of another COVID wave, new variants have appeared leading this wave. EG.5 (“Eris”) is currently in the majority in the U.S.A, but a very... 
Via Benzinga
Exposures COVID-19
Financial Crime Weekly: Pfizer Statistician's $214,000 Trade Leads To Charges
Amit Dagar, once a trusted statistician for pharmaceutical behemoth Pfizer Inc (NYSE: PFE), and Atul Bhiwapurkar, his close business ally, now find themselves mired in allegations that could see their... 
Via Benzinga
More Than Half Of Americans Want New COVID-19 Booster, But Ron DeSantis Will Fight Virus With His Charisma Alone
New COVID-19 boosters have been approved by the U.S. FDA in the fight against new variants. A new survey showed how likely people are to get new boosters and if they will have their children get... 
Via Benzinga
Exposures COVID-19 Product Safety
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders  
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now. 
Via InvestorPlace
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug. 
Via Investor's Business Daily
Exposures Product Safety
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
These stocks offer some mouth-watering payouts. 
Via The Motley Fool
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now
This market is currently in its infancy. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.